कंपनी का अवलोकन
XTL Biopharmaceuticals Ltd. operates as a specialized biopharmaceutical entity focused on the acquisition and development of pharmaceutical drugs designed for the treatment of autoimmune diseases within the Israeli market. The company functions within the Healthcare sector and specifically within the Biotechnology industry, which implies a high-risk, high-reward environment characterized by significant research and development expenditures before commercial viability is achieved. This enterprise maintains a relatively small operational scale, employing a workforce of 10 individuals while managing a total market capitalization of $5.54M. Its annual revenue generation over the trailing twelve months stands at $968,000, indicating that the company is currently in an early-stage development phase where revenue from commercial sales is minimal compared to development costs. The modest market cap and low revenue figures suggest that the company's primary value proposition lies in its pipeline assets, specifically its lead drug candidate hCDR1, rather than in current operational cash flows or established market dominance.
वित्तीय स्वास्थ्य
The company reported revenue of $968,000 over the trailing twelve months, yet it recorded a net income loss of $-6,308,000, revealing a substantial gap that highlights a cost structure dominated by heavy research and development expenses that far exceed current sales income. EBITDA data is not available for this entity, suggesting that operating earnings before interest, taxes, depreciation, and amortization are not yet positive enough to be reported in standard financial summaries. Free cash flow figures are also not available, indicating that the company is burning cash to fund its operations and drug development efforts rather than generating surplus liquidity for distribution. The gross margin stands at -232.9%, the operating margin is -853.6%, and the profit margin is 0.0%, collectively indicating that the company is incurring losses at every level of its financial hierarchy due to the high upfront costs typical of biotechnology firms. On the balance sheet, the company holds $259,000 in cash against total debt obligations of $86,000, which provides a positive liquidity buffer, although the debt-to-equity ratio is not available to quantify leverage precisely. The current ratio is reported at 0.70, indicating that the company's current assets do not fully cover its current liabilities, which suggests a potential constraint on short-term liquidity and an ability to meet obligations only with careful cash management. Return on Equity is -577.1% and Return on Assets is -240.6%, metrics that reveal that management is currently utilizing shareholder and asset bases to generate significant losses rather than profits, a common characteristic during the pre-revenue stages of pharmaceutical development.
मूल्यांकन आकलन
Trailing P/E and forward P/E ratios are not available for XTL Biopharmaceuticals Ltd., which implies that without consistent positive earnings, traditional earnings-based valuation multiples cannot be applied to assess the stock's expected earnings trajectory. The price-to-book ratio is not available, making it impossible to directly compare the market premium over the company's book value using this specific metric. However, the price-to-sales ratio is 5.72, and EV/EBITDA is not available; these alternative valuation metrics suggest that the market is pricing the company primarily on its sales potential and asset value rather than its earnings power. The stock has experienced significant volatility, trading within a 52-week range between a low of $2.12 and a high of $10.28. Given the lack of a current price in the provided facts, the specific percentage distance from the high or low cannot be calculated, but the wide range of $8.16 indicates high price sensitivity. The beta value is 0.68, which means the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market fluctuations despite its high-risk nature as a small-cap biotech firm.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not available, preventing a direct comparison of whether earnings are growing faster or slower than revenue in recent periods. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that the company retains all available capital to reinvest into its drug development pipeline and operational growth rather than distributing income to shareholders. Since the company is not a dividend payer, its strategy focuses entirely on capitalizing its earnings into growth initiatives to advance its lead drug candidate hCDR1 through Phase II readiness for systemic lupus erythematosus and Sjogren's syndrome. Overall, the growth and income profile is characterized by a reliance on future commercialization of pharmaceutical assets rather than current dividend income or historical growth rates, typical of early-stage biotechnology enterprises.